Published in Clin Cancer Res on January 26, 2010
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med (2013) 1.21
Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol (2011) 1.13
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07
Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics (2012) 0.94
Biomarkers for pancreatic cancer: recent achievements in proteomics and genomics through classical and multivariate statistical methods. World J Gastroenterol (2014) 0.86
Institutional risk factors for norovirus outbreaks in Hong Kong elderly homes: a retrospective cohort study. BMC Public Health (2011) 0.85
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer (2013) 0.83
Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PLoS One (2011) 0.78
Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. J Gastrointest Oncol (2016) 0.76
Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database. ACS Chem Biol (2016) 0.76
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Kepler planet-detection mission: introduction and first results. Science (2010) 6.23
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med (2006) 4.42
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93
Longevity of materials for pit and fissure sealing--results from a meta-analysis. Dent Mater (2011) 3.56
Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet (2011) 3.54
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol (2006) 2.73
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Multiple levels of regulation of the interleukin-6 system in stroke. Stroke (2003) 2.61
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
GlobalANCOVA: exploration and assessment of gene group effects. Bioinformatics (2007) 2.24
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res (2006) 2.13
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs (2007) 2.08
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07
Course of platelet activation markers after ischemic stroke. Stroke (2002) 2.05
Factors affecting and affected by user acceptance of computer-based nursing documentation: results of a two-year study. J Am Med Inform Assoc (2003) 2.05
Involving Medical Students in Informed Consent: A Pilot Study. World J Surg (2015) 1.97
Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Mol Biol Cell (2005) 1.92
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90
Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol (2007) 1.88
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol (2011) 1.85
Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res (2004) 1.84
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase. J Biol Chem (2004) 1.71
Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69
Multiple testing on the directed acyclic graph of gene ontology. Bioinformatics (2008) 1.69
A prospective randomized study to assess the efficacy of a surgical sealant to treat air leaks in lung surgery. Eur J Cardiothorac Surg (2009) 1.68
Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One (2009) 1.68
Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol (2009) 1.66
Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol (2005) 1.60
Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie (2007) 1.51
A compendium to ensure computational reproducibility in high-dimensional classification tasks. Stat Appl Genet Mol Biol (2004) 1.48
Long-term prophylactic treatment of attacks of vertigo in Menière's disease--comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol (2008) 1.48
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta (2010) 1.47
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. Anticancer Drugs (2013) 1.42
The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41
Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci (2009) 1.41
Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol (2005) 1.39
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev (2012) 1.38
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J (2006) 1.37
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci (2013) 1.31
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol (2013) 1.30
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malar J (2005) 1.28
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int J Colorectal Dis (2005) 1.28
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP (2006) 1.27
Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem (2005) 1.27
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum (2002) 1.24
Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol (2007) 1.23
Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health (2005) 1.23
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
Clinical effectiveness of photodynamic therapy in the treatment of periodontitis. J Clin Periodontol (2009) 1.23
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One (2008) 1.22